Dong-A ST Co., Ltd. (170900.KS)
KRW 45000.0
(0.9%)
KRW 45000.0
(0.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 663.98 Billion KRW | 4.5% |
| 2022 | 635.39 Billion KRW | 7.11% |
| 2021 | 593.22 Billion KRW | 1.11% |
| 2020 | 586.72 Billion KRW | -4.18% |
| 2019 | 612.31 Billion KRW | 7.91% |
| 2018 | 567.43 Billion KRW | 2.24% |
| 2017 | 555.02 Billion KRW | -0.98% |
| 2016 | 560.53 Billion KRW | -3.52% |
| 2015 | 580.99 Billion KRW | 0.41% |
| 2014 | 578.64 Billion KRW | 15.5% |
| 2013 | 500.96 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 155.36 Billion KRW | -14.19% |
| 2024 Q2 | 172.38 Billion KRW | 10.95% |
| 2023 Q2 | 169.2 Billion KRW | 15.02% |
| 2023 Q3 | 166.59 Billion KRW | -1.54% |
| 2023 Q1 | 147.11 Billion KRW | -4.57% |
| 2023 Q4 | 181.06 Billion KRW | 8.68% |
| 2023 FY | 663.98 Billion KRW | 4.5% |
| 2022 Q4 | 154.16 Billion KRW | -4.64% |
| 2022 Q2 | 163.3 Billion KRW | 4.51% |
| 2022 Q1 | 156.25 Billion KRW | 2.18% |
| 2022 FY | 635.39 Billion KRW | 7.11% |
| 2022 Q3 | 161.66 Billion KRW | -1.0% |
| 2021 Q1 | 140.92 Billion KRW | 9.92% |
| 2021 Q3 | 151.86 Billion KRW | 2.94% |
| 2021 Q4 | 152.92 Billion KRW | 0.7% |
| 2021 FY | 593.22 Billion KRW | 1.11% |
| 2021 Q2 | 147.52 Billion KRW | 4.68% |
| 2020 Q3 | 145.61 Billion KRW | 30.45% |
| 2020 FY | 586.72 Billion KRW | -4.18% |
| 2020 Q2 | 111.62 Billion KRW | -44.54% |
| 2020 Q1 | 201.28 Billion KRW | 28.82% |
| 2020 Q4 | 128.19 Billion KRW | -11.96% |
| 2019 FY | 612.31 Billion KRW | 7.91% |
| 2019 Q4 | 156.24 Billion KRW | -3.4% |
| 2019 Q3 | 161.74 Billion KRW | 6.68% |
| 2019 Q2 | 151.62 Billion KRW | 6.26% |
| 2019 Q1 | 142.69 Billion KRW | 3.04% |
| 2018 Q2 | 152.57 Billion KRW | 12.4% |
| 2018 FY | 567.43 Billion KRW | 2.24% |
| 2018 Q3 | 140.64 Billion KRW | -7.82% |
| 2018 Q4 | 138.48 Billion KRW | -1.53% |
| 2018 Q1 | 135.73 Billion KRW | -6.59% |
| 2017 Q2 | 132.73 Billion KRW | -0.28% |
| 2017 Q1 | 133.1 Billion KRW | 7.02% |
| 2017 Q3 | 143.87 Billion KRW | 8.4% |
| 2017 FY | 555.02 Billion KRW | -0.98% |
| 2017 Q4 | 145.31 Billion KRW | 1.0% |
| 2016 Q4 | 124.37 Billion KRW | -8.81% |
| 2016 FY | 560.53 Billion KRW | -3.52% |
| 2016 Q1 | 150.51 Billion KRW | 4.24% |
| 2016 Q2 | 157.55 Billion KRW | 4.68% |
| 2016 Q3 | 136.4 Billion KRW | -13.43% |
| 2015 FY | 580.99 Billion KRW | 0.41% |
| 2015 Q3 | 151.93 Billion KRW | 6.7% |
| 2015 Q2 | 142.39 Billion KRW | 0.09% |
| 2015 Q1 | 142.27 Billion KRW | -2.28% |
| 2015 Q4 | 144.38 Billion KRW | -4.97% |
| 2014 Q1 | 146.67 Billion KRW | -3.83% |
| 2014 Q2 | 150.3 Billion KRW | 2.47% |
| 2014 Q3 | 136.05 Billion KRW | -9.48% |
| 2014 Q4 | 145.59 Billion KRW | 7.01% |
| 2014 FY | 578.64 Billion KRW | 15.5% |
| 2013 Q2 | 146.2 Billion KRW | 202.45% |
| 2013 FY | 500.96 Billion KRW | 0.0% |
| 2013 Q1 | 48.33 Billion KRW | 0.0% |
| 2013 Q3 | 153.89 Billion KRW | 5.26% |
| 2013 Q4 | 152.52 Billion KRW | -0.89% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -83.873% |
| Yuhan Corporation | 1858.98 Billion KRW | 64.283% |
| Yuhan Corporation | 1858.98 Billion KRW | 64.283% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -383.917% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -383.917% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -383.917% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -3.999% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -238.169% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 41.345% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 11.295% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 11.295% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 11.295% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1177.99% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 24.529% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -649.468% |
| HANDOK Inc. | 522.74 Billion KRW | -27.019% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 16.45% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -390.483% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -427.269% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -660.019% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -750.676% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -26.004% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -182.662% |
| Boryung Corporation | 859.62 Billion KRW | 22.759% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -267.322% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -127.29% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -79.194% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -79.194% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -11.675% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 56.157% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -392.166% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -188.194% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -291.573% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -231.611% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -231.611% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -138.034% |
| CKD Bio Corp. | 160.35 Billion KRW | -314.075% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 51.722% |
| JW Holdings Corporation | 928.07 Billion KRW | 28.456% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -339.515% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 55.464% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 60.227% |
| JW Lifescience Corporation | 206.86 Billion KRW | -220.98% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -10.524% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 8.592% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -195.816% |